Contribute Try STAT+ Today

As researchers rummage through a pantry of potential next-generation immunotherapies, they have developed a handful of new technologies they hope can be deployed against cancer: Natural killer cells. Neoantigen vaccines. Tumor-infiltrating lymphocytes.

Then there are T cell receptor, or TCR, therapies. In some ways, they’re similar to the CAR-T therapies that are already being used to treat some patients. But their potential to swarm and invade difficult-to-treat cancers, including solid tumors, has spurred hopes that they can significantly expand the population of patients who respond to immunotherapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy